The rise of drug resistance has left us facing a future with few effective antibiotics. Do the next-generation antibiotics in the pipeline offer hope?

With an EMA pilot scheme underway it looks likely that adaptive licensing will feature in the future drug development landscape.

Hiring gifted new employees is tough enough, but how do you keep them within your organization once you’ve got them?

Sitting Down With… Nick Haggar, Head of Western Europe, Middle East & Africa, Sandoz, and President of the European Generic Medicines Association (EGA).

The US is finally introducing regulation on drug serialization and traceability, but gaps remain that could leave patients vulnerable.

Mysterious cyber attackers are hitting pharma manufacturing systems

New Alzheimer’s treatment gets $500 million collaborative boost

Opportunistic investors surf the wave of experimental treatments

New NIH policies aim to correct the sex bias in preclinical research.

Merck KGaA snaps up Sigma-Aldrich, Allergan fights Valeant, and Shire–Abbvie deal sours